Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 20/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | PTGIS | Q16647 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10973204 | 1.00 | TBXAS1 (1.00) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL10974315 | 1.00 | TBXAS1 (1.00) | TBXAS1PTGS1PTGS2PTGIS | |
| Pirmagrel SCHEMBL11069774 | 0.99 | TBXAS1 (0.97) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL10980923 | 0.99 | TBXAS1 (1.00) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL10975502 | 0.89 | TBXAS1 (1.00) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL11200340 | 0.89 | TBXAS1 (0.80) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL7820852 | 0.85 | TBXAS1 (1.00) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL10978485 | 0.84 | TBXAS1 (1.00) | TBXAS1PTGS1PTGS2PTGIS | |
| Hydrochloric Acid SCHEMBL10978209 | 0.83 | TBXAS1 (1.00) | TBXAS1PTGS1PTGS2PTGIS | |
| SCHEMBL10978084 | 0.82 | TBXAS1 (1.00) | TBXAS1PTGS1PTGS2PTGIS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040483-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8425892-B2 | Containing crosslinked polymer and active material | COLUMBIA LABORATORIES, INC. (US) | 2013-04-23 | — | — | US | claimed |
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | BIOVASCULAR, INC. | 2013-01-24 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| JP-2011524416-A | — | — | 2011-09-01 | — | — | JP | claimed |
| CN-102123699-A | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR INC | 2011-07-13 | — | — | CN | claimed |
| EP-2306985-A2 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | Biovascular, Inc. (US) | 2011-04-13 | — | — | EP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| WO-2003037381-A1 | VAGINALLY ADMINISTERD ANTI-DYSRHYTHMIC AGENTS FOR TREATING PELVIC PAIN AND INFERTILITY | COLUMBIA LABORATORIES (BERMUDA) LIMITED (BM) | 2003-05-08 | — | — | WO | claimed |
| EP-0351755-B1 | COMBINATION OF A CALCIUM CHANNEL BLOCKER AND THROMBOXANE A2 RECEPTOR ANTAGONIST OR SYNTHETASE INHIBITOR AND METHOD FOR TREATING ISCHEMIA EMPLOYING SUCH COMBINATION | E.R. SQUIBB & SONS, INC. (US) | 1992-09-30 | — | — | EP | claimed |
| EP-0449764-A2 | A method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor and/or thromboxane receptor antagonist | CIBA-GEIGY AG (CH) | 1991-10-02 | — | — | EP | claimed |
| US-5021448-A | Method of reducing serum uric acid and/or increasing renal uric acid clearance with thromboxane synthetase inhibitor inhibitor and/or thromboxane receptor antagonist | CIBA-GEIGY CORPORATION (US) | 1991-06-04 | — | — | US | claimed |
| US-4925869-A | REACTIVATING ENZYME ACETYLCHOLINESTERASE INHIBITED BY LETHAL DOSE OF SOMAN | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-05-15 | — | — | US | claimed |
| US-4908380-A | Substituted 1,3-dioxane ether derivative; thromboxane A2 inhibitor | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-03-13 | — | — | US | claimed |
| EP-0351755-A1 | Combination of a calcium channel blocker and thromboxane A2 receptor antagonist or synthetase inhibitor and method for treating ischemia employing such combination | E.R. SQUIBB & SONS, INC. (US) | 1990-01-24 | — | — | EP | claimed |
| EP-0068386-B1 | SUBSTITUTED IMIDAZO(1,5-A)PYRIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS | CIBA-GEIGY AG (CH) | 1985-12-18 | — | — | EP | claimed |
| US-4444775-A | ENZYME INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1984-04-24 | — | — | US | claimed |
| EP-0068386-A1 | Substituted imidazo(1,5-a)pyridines, process for their preparation and pharmaceutical preparations containing these compounds | CIBA-GEIGY AG (CH) | 1983-01-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022671-A1 | CONTROLLED RELEASE COMPOSITIONS OF AGENTS THAT REDUCE CIRCULATING LEVELS OF PLATELETS AND METHODS THEREFOR | SERPINC1, PLAT, MPL | TBXAS1 42/4885PTGS1 67/4885PTGS2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.